Internal medicine

Clinical endpoint

Stroke (engine)

Population

Myocardial infarction

Ischemia

Engineering

Surgery

Randomized controlled trial

Tissue plasminogen activator

Tenecteplase

Thrombolysis

Modified Rankin Scale

Fibrinolytic agent

Ischaemic stroke

Ischemic stroke

Clinical trial

Medicine

Mechanical engineering

Environmental health

The Lancet Neurology

In this prematurely terminated study (terminated to fulfil the prespecified safety criteria), tenecteplase at a dose of 0·4 mg/kg yielded worse safety and functional outcomes compared with alteplase. Our study consequently could not show that 0·4 mg/kg tenecteplase is non-inferior to alteplase in moderate and severe ischaemic stroke. Future stroke trials should assess a lower dose of tenecteplase versus alteplase in patients with moderate or severe stroke.

Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint, non-inferiority trial